Hysteroscopy Procedures Market Size, Share & Trends Analysis Report By End Use (Ambulatory Surgical Centers, Hospitals, Clinics), By Region (Asia Pacific, Europe, North America), And Segment Forecasts, 2021 - 2028

Report Overview

The global hysteroscopy procedures market size was valued at USD 3.83 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.7% from 2021 to 2028. The increasing prevalence of gynecological disorders, such as uterine abnormalities, abnormal uterine bleeding, uterine fibroids, and fertility disorders, is a key factor driving the market growth. Moreover, the rising adoption of minimally invasive surgeries over traditional methods and technological advancements are other major factors fueling the market growth. The impact of the COVID-19 pandemic has been significant on the market. The unprecedented surge of COVID-19 cases globally has led to inadequate care for patients suffering from other diseases.

This resulted in hospitals prioritizing emergency procedures and delaying/postponing elective surgeries, including gynecological procedures, which led to a surfeit of patients waiting for their surgeries for months. CovidSurg Collaborative study 2020 has projected that around 28.4 million elective surgeries, including 81.7% benign surgeries worldwide, were canceled or postponed in 2020, owing to disruption in medical services due to the pandemic. However, with ease of restrictions, many elective procedures are now restarting; hence, the market is expected to recover gradually.

The rising incidence of uterine cancer has increased the number of hysteroscopy procedures, thereby accelerating market growth. Uterine cancer is one of the most prevalent gynecological disorders globally and its prevalence is rising at an exponential rate. This upsurge is driven by the increasing prevalence of obesity, as it increases the risk of uterine cancer. For instance, according to the American Cancer Society, 66,570 new uterine cancer cases are likely to be diagnosed in 2021. Around 12,940 deaths are predicted due to uterine cancer in 2021.

Nowadays, minimally invasive surgical procedures are gaining popularity owing to the reduced risk associated with these procedures. Minor incisions reduce postoperative pain and enable speedy recovery, leading to high adoption of these procedures. For instance, hysteroscopy is associated with reduced hospitalizations, faster recovery, and less blood loss. Moreover, hysteroscopy induces less postoperative pain and abdominal wound. Thus, an increase in patient preference for noninvasive or minimally invasive treatment and benefits offered by these techniques are anticipated to boost market growth at a significant rate during the forecast period.

Moreover, several key players are investing in R&D for the launch of innovative minimally and non-invasive surgical instruments. Lately, several technologically advanced hysteroscopes are available in the market and can be customized according to the planned procedure. For instance, in July 2021, Meditrina, Inc. launched a disposable Aveta auto resecting device and single-use Aveta Opal hysteroscope. This new launch will help the firm expand its hysteroscopic tissue resection product portfolio, thereby strengthening its market position.

Furthermore, leading industry players, such as Hologic, Inc., CooperSurgical, Inc., Stryker Corp., Karl Storz GmbH, Medtronic, Delmont Imaging, and Johnson and Johnson Services, Inc., are engaged in intensive R&D activities to manufacture innovative products and are making continuous efforts to introduce technologically sophisticated products to the market. For instance, iCare developed by Delmont Imaging comprises an imaging solution imagyn, which is an advanced hysteroscopy database management application. It enables monitoring of hysteroscopy examination directly on an iPad Pro over private & secured Wi-Fi. In February 2021, VirtaMed launched an authorized combined mixed reality training platform for hysteroscopy and gynecological laparoscopy. Such developments are expected to further boost the market growth.

End-use Insights

On the basis of end use, the market has been segmented into hospitals, clinics, and Ambulatory Surgery Centers (ASCs). The hospitals segment accounted for the largest revenue share of over 52% in 2020 due to a significantly high inflow of patients for gynecological procedures as compared to other healthcare settings as hospitals can handle any emergencies that may arise during and after surgical procedures. Moreover, hospitals offer a broad range of treatment options, which will drive the segment over the forecast years. For instance, according to the NCBI, around 30,000 myomectomies are performed annually for leiomyomata (fibroids) in the U.S. Moreover, hospitals are the primary health system in the majority of countries; therefore, the number of hysteroscopy procedures done at hospitals is relatively high than in other healthcare settings.

The ASCs segment is expected to exhibit the highest CAGR of 7.00% during the forecast period. Increased preference for outpatient procedures might surge the usage of hysteroscopy procedures in ASCs, boosting the segment growth. Outpatient (ambulatory) hysteroscopy is conducted outside the formal setting of an operation theater in a suitably equipped and staffed treatment room. This offers patient comfort and reduces the required time for diagnostic hysteroscopy. Moreover, it is efficient and economical for both patients and surgeons as the setup includes an examination room and does not require an additional operating suite. Hysteroscopy in the ambulatory setting has shown accuracy and patient acceptability equivalent to inpatient hysteroscopy procedures; hence, ambulatory hysteroscopy is rapidly advancing in the field of gynecological practice.

Regional Insights

North America dominated the global market with a revenue share of over 38% in 2020 and will expand further at a steady CAGR from 2021 to 2028. This can be attributed to favorable government regulations & reimbursement policies, the presence of key market players, growing approval & commercialization of products, and high awareness regarding the availability of diagnostic tests & treatments. Furthermore, the rising demand for minimally invasive procedures and increasing investments in the R&D of gynecological systems are among the factors responsible for market growth in the region. For instance, in August 2018, the U.S. FDA approved Luminelle DTx Hysteroscopy System by UVision360 for both hysteroscopy and cystoscopy. The system allows physicians to perform in-office hysteroscopic procedures, such as biopsy, and detect abnormal tissue growth. Thus, the ease of access to healthcare technologies, the presence of strong distribution channels, and competition among prominent players related to product innovation are contributing to market growth in this region.

Asia Pacific is expected to be the fastest-growing regional market during the forecast period. The presence of a large patient pool and the growing need for technologically advanced & cost-effective healthcare solutions are among factors expected to present significant growth opportunities in the market. Moreover, an increase in the number of clinical trials and high R&D investments by global market players to enter untapped markets in Asia Pacific region, owing to low-cost services, are high-impact rendering drivers of the market. Moreover, the rising incidence of diseases related to women’s health and subsequently increasing the number of surgeries are expected to boost the regional market growth over the forecast period. Singapore and South Korea are some of the emerging economies in Asia Pacific. Advancing technology, increasing investments, improving reimbursement scenarios, and growing medical tourism are among the factors expected to drive the region’s growth.

Key Companies & Market Share Insights

Key players are involved in adopting strategies, such as mergers & acquisitions, partnerships, and new product launches, to strengthen their foothold in the global market. For instance, in February 2021, CooperSurgical, Inc. acquired AEGEA Medical. The acquisition will help the firm expand its product portfolio of women's health.

In January 2021, Hologic, Inc. launched a Fluent Fluid Management System, a CE-marked system, in Europe. This new system is designed to help maintain consistent intracavity pressure and uterine distention. This launch helped the company strengthen its market position and expand its hysteroscopy product line. Some prominent players in the global hysteroscopy procedures market include:

• Medtronic

• Stryker Corp.

• Hologic, Inc.

• KARL STORZ SE & Co. KG

• Medical Devices Business Services, Inc. (Ethicon, Inc.)

• Olympus Corp.

• Delmont Imaging

• B. Braun Melsungen AG

• Richard Wolf GmbH

• CooperCompanies

• Maxer Endoscopy GmbH

• Boston Scientific Corp.

• MedGyn Products, Inc.

• Lina Medical APS

• Luminelle

• Meditrina, Inc. (Aveta)

Hysteroscopy Procedures Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global hysteroscopy procedures market report on the basis of end use and region:

• End-use Outlook (Revenue, USD Million, 2016 - 2028)

  • Hospitals

  • Clinics

  • Ambulatory Surgery Centers (ASCs)

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Norway

    • Sweden

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Turkey

    • Qatar